Boston Scientific Corporation (NYSE:BSX) Stock Has Consensus Price Target of $61.43

Boston Scientific logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts broadly favor Boston Scientific: 21 of 31 covering firms rate the stock Buy or Strong Buy, giving it a consensus “Moderate Buy” rating and an average 12-month price target of $61.43.
  • Recent analyst actions were mixed, including rating downgrades and price-target cuts; BSX opened at $43.70, well below its 200-day moving average of $53.75.
  • In its latest quarter, the company met EPS expectations at $0.73 and slightly beat revenue estimates with $5.14 billion; revenue rose 1.4% year over year.
  • Five stocks we like better than Boston Scientific.

Shares of Boston Scientific Corporation (NYSE:BSX - Get Free Report) have earned an average rating of "Moderate Buy" from the thirty-one research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, twenty have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $61.43.

Several equities analysts have recently commented on BSX shares. Oppenheimer cut shares of Boston Scientific from an "outperform" rating to a "market perform" rating in a report on Thursday, October 29th. UBS Group cut their price objective on Boston Scientific from $67.00 to $57.00 and set a "buy" rating for the company in a report on Thursday, October 29th. Deutsche Bank set a $48.00 price objective on Boston Scientific and gave the company a "buy" rating in a research report on Thursday, October 29th. Weiss Ratings restated a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Finally, Royal Bank Of Canada dropped their target price on Boston Scientific from $70.00 to $52.00 and set an "outperform" rating on the stock in a research report on Thursday, October 29th.

Check Out Our Latest Research Report on Boston Scientific

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently modified their holdings of BSX. BlackRock Inc. bought a new stake in shares of Boston Scientific in the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific during the second quarter worth $2,156,233,000. Jupiter Topco LLC bought a new position in Boston Scientific during the second quarter worth $803,357,000. Janus Henderson Group PLC raised its stake in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Finally, Dodge & Cox raised its stake in Boston Scientific by 17,001.4% during the 3rd quarter. Dodge & Cox now owns 14,961,119 shares of the medical equipment provider's stock valued at $653,053,000 after purchasing an additional 14,873,634 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $43.70 on Thursday. The company's fifty day moving average is $43.85 and its two-hundred day moving average is $53.75. The company has a market cap of $63.34 billion, a P/E ratio of 18.52, a price-to-earnings-growth ratio of 1.27 and a beta of 0.60. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $101.91. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the firm earned $0.75 earnings per share. The firm's revenue was up 1.4% compared to the same quarter last year. Equities analysts expect that Boston Scientific will post 3.17 earnings per share for the current fiscal year.

About Boston Scientific

(Get Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

See Also

Analyst Recommendations for Boston Scientific (NYSE:BSX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines